Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2003
10/23/2003WO2003086371A2 Use of ep4 receptor ligands in the treatment of il-6 involved diseases
10/23/2003WO2003086356A1 Diphenhydramine tannate solid dose compositions and methods of use
10/23/2003WO2003086354A1 Nanoparticulate megestrol formulations
10/23/2003WO2003086352A1 Pharmaceutical formulation comprising melatonin
10/23/2003WO2003086351A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
10/23/2003WO2003086346A1 Diphenhydramine tannate compositions and methods of use
10/23/2003WO2003086344A1 Antibiotic product, use and formulation thereof
10/23/2003WO2003086324A2 Preparation and use of a stable formulation of allosteric effector compounds
10/23/2003WO2003086323A2 Compositions and methods for immunomodulation
10/23/2003WO2003086315A2 Tyrosine kinase inhibitors
10/23/2003WO2003086314A2 Tyrosine kinase inhibitors
10/23/2003WO2003086311A2 Methods for treating tweak-related conditions
10/23/2003WO2003086308A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
10/23/2003WO2003086298A2 Use of interleukin-19 to treat ovarian cancer
10/23/2003WO2003086282A2 Nitric oxide donors, compositions and methods of use
10/23/2003WO2003086280A2 Immunostimulatory g,u-containing oligoribonucleotides
10/23/2003WO2003086279A2 Inhibitors of akt activity
10/23/2003WO2003086267A2 Multi-phase, multi-compartment capsular system
10/23/2003WO2003086097A1 Composition for modulating a physiological reaction or inducing an immune response
10/23/2003WO2003086041A2 Binding agents and their use in targeting tumor cells
10/23/2003WO2003068929A9 Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors
10/23/2003WO2003057252A8 Human mast cell-expressed membrane proteins
10/23/2003WO2003051315A3 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
10/23/2003WO2003048773A3 Methods for monitoring amyotrophic lateral sclerosis
10/23/2003WO2003047522A3 Composition and method for decreasing upper respiratory airway resistance
10/23/2003WO2003045523A3 Therapeutic coating for an intravascular implant
10/23/2003WO2003043966A3 Clusianon isomers and use thereof
10/23/2003WO2003039473A3 Method for treating or preventing inflammatory diseases
10/23/2003WO2003035047A3 Combinations comprising a selective cyclooxygenase-2 inhibitor
10/23/2003WO2003029410A3 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER
10/23/2003WO2002077216A3 Ikk2 variant, dino gene, lectin-like receptor gene, and proteins encoded thereby
10/23/2003WO2002074034A3 Novel medicament compositions based on anticholinergic agents and endothelin antagonists
10/23/2003WO2002067688A8 Noninvasive measurements of chemical substances
10/23/2003WO2002046384A3 Kinases and phosphatases sequences, and use thereof
10/23/2003WO2002044321A3 Rna interference mediating small rna molecules
10/23/2003WO2002042272A8 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
10/23/2003WO2001055337A9 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
10/23/2003WO2001045641A8 Inhibitors of thrombin induced platelet aggregation
10/23/2003WO2001039765A8 Compositions and methods for the induction and treatment of retinal detachments
10/23/2003WO2001027635A8 Multiwell scanner and scanning method
10/23/2003WO2001009328A8 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
10/23/2003WO2001002567A8 16405 receptor, a g-protein coupled receptor
10/23/2003US20030199589 Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses
10/23/2003US20030199567 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
10/23/2003US20030199565 Gastrin and cholecystokinin receptor ligands(II)
10/23/2003US20030199563 Heterocyclic containing biphenyl aP2 inhibitors and method
10/23/2003US20030199557 Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
10/23/2003US20030199551 Calcium blockers to treat proliferative vitreoretinopathy
10/23/2003US20030199546 6-(((2S)-2-(alkoxycabonyl)-4,4-difluoropyrrolidinyl)methyl)-1, 2, 3.4, 4a, 5, 6, 7, 8, 8a-decahydroisoquinoline-3-carboxylate, or acid derivatives, useful for treating migraine, and dural protein extravasation
10/23/2003US20030199545 New esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
10/23/2003US20030199535 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
10/23/2003US20030199529 Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
10/23/2003US20030199527 Such as 3-((4-methyl-benzyl)-(3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo -(3,4-d)pyrimidin-4-yl)-amino)prop an-1-ol for treating/preventing Syndrome X; kits
10/23/2003US20030199526 Pyrimidine-based compounds useful as GSK-3 inhibitors
10/23/2003US20030199516 Methods of treating infection by drug resistant bacteria
10/23/2003US20030199509 For treatment of glaucoma and/or ocular hypertension
10/23/2003US20030199507 Combination of brimonidine and timolol for topical ophthalmic use
10/23/2003US20030199498 Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
10/23/2003US20030199496 Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
10/23/2003US20030199492 Combination therapy
10/23/2003US20030199489 Small molecule inhibitors targeted at BCL-2
10/23/2003US20030199485 Novel anti-inflammatory androstane derivative
10/23/2003US20030199483 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
10/23/2003US20030199482 Anticholesterol agents; a drug mixture for treating hypercholesterolemia comprising an apical sodium co-dependent bile acid transport inhibitor, enzyme inhibitors of a cyclooxygenase-2
10/23/2003US20030199477 Use of gellable pharmaceutical compositions in periodontology
10/23/2003US20030199464 Regeneration of endogenous myocardial tissue by induction of neovascularization
10/23/2003US20030199463 For therapy of cardiovascular disease, fibrotic disease
10/23/2003US20030199457 Prevention and treatment of thromboembolic disorders associated with arterial & venous thrombosis
10/23/2003US20030199456 Sodium channel blockers
10/23/2003US20030199444 Comprising a preparation of Blood Factor VII or a Factor VII-related polypeptide and a preparation of factor VIII (antihemophilic factor) or a factor VIII-related polypeptide; high speed coagulants in one dosage form; kits; hemostatis
10/23/2003US20030199440 Comprises a growth factor and an enzyme inhibitor for a specific adverse enzyme that is upregulated in the environment of a damaged tissue; wound healing agents; antiulcer agents; chronic wounds, e.g. decubitus ulcers
10/23/2003US20030199439 Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
10/23/2003US20030199432 Coadministration of a lysostaphin or other antistaphylococcal agent which cleaves glycine crosslinks of the peptidoglycans of staphylococci cell walls and an antibiotic effective due to the cell wall activity, e.g., beta lactams and glycopeptides
10/23/2003US20030199427 Increased or improved bioavailability of the active agent
10/23/2003US20030199426 Combination of a saturated or unsaturated fatty alcohol or fatty acid; a C1/C4 alkanol; a polyalcohol in particular propylenglycol; water; and optionally a monoalkylether of diethylene glycol as a permeation enhancer
10/23/2003US20030199424 of a neuropathic condition, by administering anangiotensin II receptor I (AT1 receptor) antagonists
10/23/2003US20030199002 For the treatment, management, or prevention of disorders associated with abnormal expression and/ or activity of clk-2 (clock-2) nucleic acids; treating or preventing disorders associated with decreased/increased apoptosis e.g. cancer
10/23/2003US20030198982 Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses
10/23/2003US20030198975 Proteins associated with cell growth, differentiation, and death
10/23/2003US20030198954 For forensic analyses, chromosome tissue/cell/organelle-specific markers, production of expression vectors, screening and diagnosis assays
10/23/2003US20030198821 Polyurethane-urea-silane copolymer for use as coatings that are elastic when dry, lubricious when wet, and resist wet abrasion; for coating rubber, medical devices (catheters, shunts)
10/23/2003US20030198727 Oil/fat composition
10/23/2003US20030198692 Red algae extract; human, veterinary medicine; mixture of cell permeability agent and microbiocide
10/23/2003US20030198689 Nontoxic aqueous solution; electrolysis; bactericide, viricide
10/23/2003US20030198682 Encapsulation cosmetic in water soluble polysaccharides; topical applying to human skins
10/23/2003US20030198643 Adjuvant enhanced immunotherapy
10/23/2003US20030198637 Antiproliferative agent; induction apoptosis; antitumor agents
10/23/2003US20030198636 Prevent completitive binding; amplification inflammation response; convertase inhibitor; side effect reduction
10/23/2003EP1494675A2 Inhibitors of akt activity
10/23/2003DE20310493U1 Micronutrient combination product for dietetic treatment of inflammatory-rheumatic diseases and osteoporosis, containing specific amounts of several vitamins, minerals, trace elements and antioxidants
10/23/2003CA2483451A1 Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
10/23/2003CA2482718A1 Derivatives of the il-2 receptor gamma chain, their production and use
10/23/2003CA2482634A1 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signal transduction
10/23/2003CA2482612A1 Use of substances for treatment of tumors
10/23/2003CA2482387A1 Derivatives of the nf-kappab inducing enzyme, their preparation and use
10/23/2003CA2481796A1 Binding agents and their use in targeting tumor cells
10/23/2003CA2481752A1 Composition for modulating a physiological reaction or inducing an immune response
10/23/2003CA2481669A1 Preparation and use of a stable formulation of allosteric effector compounds
10/23/2003CA2481509A1 Her-2 receptor tyrosine kinase molecules and uses thereof
10/23/2003CA2481478A1 Stimulation of nerve cell regeneration
1 ... 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 ... 1151